Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

In February, the HHS unexpectedly delivered notice that the South San Francisco-based company was to stop all work on the ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

The former head of Johnson & Johnson’s worldwide medtech business, Ashley McEvoy, has signed up to lead the insulin ...

Ferrer’s R&D work focuses on neurological and pulmonary diseases, and the Spanish pharma has bought into ALS assets in the ...

Three Senate Democrats called for an investigation into the developers of brain-computer interface devices, including ...

Tonix Pharmaceuticals has no tonic for cocaine intoxication, with the biopharma terminating a midstage trial for the ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The CEO of Novo Holdings has warned that his $160 billion fund will slow down investment activity until the dust settles ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...